{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:01:05Z","timestamp":1790352065939,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The novel cream formulation of calcipotriol and betamethasone dipropionate based on polyaphron dispersion technology (CAL\/BDP PAD-cream) has shown promising results on psoriasis in phase III clinical trials. However, real-world data on scalp psoriasis\u00a0are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess clinician-reported outcomes (ClinROs) and patient-reported outcomes (PROs)\u00a0of CAL\/BDP PAD-cream in adults with mild-to-moderate scalp psoriasis under real-world conditions in Europe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PRO-SCALP is a prospective, noninterventional, multicentre, cohort study conducted between June 2023 and October 2024 in Germany, Spain and the UK. Data were collected at baseline and week 8 (end of study, EOS). PROs included the\u00a0Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9), Scalpdex\u00a0questionnaire, Worst Itch-Numerical Rating Scale (WI-NRS), sleep disturbances, the\u00a0Psychosocial Effects of Scalp Psoriasis Questionnaire and adherence. ClinROs included treatment satisfaction, Physician\u2019s Global Assessment of scalp (scalp-PGA) and scalp-modified Psoriasis Area and Severity Index (S-mPASI). The trial was registered at ClinicalTrials.gov (NCT05811234).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 253 patients had evaluable data (mean age 47.9\u2005years; 65.2% female). Of them, 59.9% reported high adherence (visual analogue scale score 80\u2013100). At EOS, the mean (SD)\u00a0global satisfaction (TSQM-9) was 76.0 (21.6) and 77.6% of patients achieved a scalp-PGA score of 0\/1 (clear\/almost clear). Moreover, 68.4% achieved scalp-PGA success (scores of 0\/1 and \u2265 2-point improvement). WI-NRS, S-mPASI and Scalpdex scores improved significantly (P &amp;lt; 0.001) from baseline to EOS. Sleep patterns and psychosocial outcomes also improved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CAL\/BDP PAD-cream is associated with high treatment satisfaction and improved clinical outcomes and quality of life in the real-world management of scalp psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag185","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:48:07Z","timestamp":1777376887000},"page":"1855-1864","source":"Crossref","is-referenced-by-count":2,"title":["Patient- and clinician-reported outcomes of calcipotriol\/betamethasone dipropionate PAD-cream for the treatment of adult patients with scalp psoriasis under real-world conditions: results from the prospective, noninterventional, multicentre PRO-SCALP study"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8816-1989","authenticated-orcid":false,"given":"Jose Luis","family":"L\u00f3pez Estebaranz","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1195-0290","authenticated-orcid":false,"given":"Anthony","family":"Bewley","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Barts Health NHS Trust & Queen Mary University , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1502","authenticated-orcid":false,"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt am Main , Frankfurt am Main ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-2129","authenticated-orcid":false,"given":"Jordi","family":"Galv\u00e1n","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Department , Almirall S.A., Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Koscielny","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Department , Almirall S.A., Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2026092511024236900_llag185-B1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"2026092511024236900_llag185-B2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s13555-021-00521-z","article-title":"Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management","volume":"11","author":"Mosca","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026092511024236900_llag185-B3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/14656566.2018.1448788","article-title":"Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas","volume":"19","author":"Kivelevitch","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2026092511024236900_llag185-B4","first-page":"33","article-title":"Management of scalp psoriasis: current perspectives","volume":"6","author":"Blakely","year":"2016","journal-title":"Psoriasis (Auckl)"},{"key":"2026092511024236900_llag185-B5","first-page":"CD009687","article-title":"Topical treatments for scalp psoriasis","volume":"2","author":"Schlager","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026092511024236900_llag185-B6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/1744666X.2020.1776116","article-title":"Calcipotriol\/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data","volume":"16","author":"Megna","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"2026092511024236900_llag185-B7","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s13555-023-01003-0","article-title":"Calcipotriol and betamethasone dipropionate cream based on PAD technology for the treatment of plaque psoriasis: a narrative review","volume":"13","author":"Torres","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026092511024236900_llag185-B8","doi-asserted-by":"crossref","first-page":"2023-2-8","DOI":"10.7573\/dic.2023-2-8","article-title":"Sensory properties analysis of a calcipotriol and betamethasone dipropionate cream vehicle formulated with an innovative PAD technology for the treatment of plaque psoriasis on the skin and scalp","volume":"12","author":"Garc\u00eda","year":"2023","journal-title":"Drugs Context"},{"key":"2026092511024236900_llag185-B9","volume-title":"Sensory properties analysis of the main pharmaceutical forms used in the topical treatment of plaque psoriasis","author":"Guil\u00e0","year":"11\u201314  2023"},{"key":"2026092511024236900_llag185-B10","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1111\/jdv.19330","article-title":"Randomized phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis","volume":"37","author":"Pinter","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026092511024236900_llag185-B11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.36849\/JDD.5653","article-title":"A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream","volume":"20","author":"Stein Gold","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"2026092511024236900_llag185-B12","doi-asserted-by":"crossref","first-page":"2357618","DOI":"10.1080\/09546634.2024.2357618","article-title":"Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey","volume":"35","author":"L\u00f3pez Estebaranz","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2026092511024236900_llag185-B13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/jvc2.70058","article-title":"Patient and clinician-reported outcomes and adherence to calcipotriene\/betamethasone dipropionate PAD-cream in treatment of scalp psoriasis in adults: an interim analysis of the PRO-SCALP Study","volume":"4","author":"Pinter","year":"2025","journal-title":"JEADV Clin Pract"},{"key":"2026092511024236900_llag185-B14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-7-36","article-title":"Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"2026092511024236900_llag185-B15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archderm.138.6.803","article-title":"Scalpdex: a quality-of-life instrument for scalp dermatitis","volume":"138","author":"Chen","year":"2002","journal-title":"Arch Dermatol"},{"key":"2026092511024236900_llag185-B16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator\u2019s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials","volume":"26","author":"Langley","year":"2015","journal-title":"J\u00a0Dermatolog Treat"},{"key":"2026092511024236900_llag185-B17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/ijd.12645","article-title":"The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis","volume":"54","author":"Naegeli","year":"2015","journal-title":"Int J Dermatol"},{"key":"2026092511024236900_llag185-B18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12895-020-00099-7","article-title":"Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort","volume":"20","author":"Egeberg","year":"2020","journal-title":"BMC Dermatol"},{"issue":"8 Suppl.","key":"2026092511024236900_llag185-B19","first-page":"s101","article-title":"Scalp psoriasis","volume":"9","author":"Kircik","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"2026092511024236900_llag185-B20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5114\/reum.2018.80718","article-title":"Psoriasis in special localizations","volume":"56","author":"Dopytalska","year":"2018","journal-title":"Reumatologia"},{"key":"2026092511024236900_llag185-B21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.36849\/JDD.6498","article-title":"Treatment of scalp psoriasis","volume":"21","author":"Ghafoor","year":"2022","journal-title":"J Drugs Dermatol"},{"issue":"Suppl. 1","key":"2026092511024236900_llag185-B22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/jdv.18751","article-title":"Engaging psoriasis patients in adherence and outcomes to topical treatments: a summary from the symposium \u2018Tailoring topical psoriasis treatments to patients\u2019 needs and expectations\u2019 of the 30th EADV Congress 2021","volume":"37","author":"Bewley","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026092511024236900_llag185-B23","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamadermatol.2021.3341","article-title":"Patient-reported outcome measures as complementary information to clinician-reported outcome measures in patients with psoriasis","volume":"157","author":"Barbieri","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026092511024236900_llag185-B24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/jdv.17734","article-title":"A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis","volume":"36","author":"Pinter","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026092511024236900_llag185-B25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ad.2012.12.005","article-title":"Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"104","author":"Puig","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"2026092511024236900_llag185-B26","first-page":"309","article-title":"Quality of life in patients with scalp psoriasis","volume":"150","author":"Zampieron","year":"2015","journal-title":"G Ital Dermatol Venereol"},{"key":"2026092511024236900_llag185-B27","doi-asserted-by":"crossref","first-page":"17541","DOI":"10.1038\/s41598-023-44757-5","article-title":"Evaluation of sleep quality and pruritus severity in psoriatic patients and their impact on quality of life: a cross section correlational study","volume":"13","author":"Zaky","year":"2023","journal-title":"Sci Rep"},{"key":"2026092511024236900_llag185-B28","first-page":"25","article-title":"Assessing and improving psychological well-being in psoriasis: considerations for the clinician","volume":"12","author":"Blackstone","year":"2022","journal-title":"Psoriasis (Auckl)"},{"issue":"Suppl.","key":"2026092511024236900_llag185-B29","doi-asserted-by":"crossref","first-page":"s9","DOI":"10.25251\/skin.6.supp.9","article-title":"Calcipotriene and betamethasone dipropionate cream demonstrates high treatment success in patients with scalp psoriasis","volume":"6","author":"Pinter","year":"2022","journal-title":"SKIN"},{"key":"2026092511024236900_llag185-B30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","article-title":"Self-report measures of medication adherence behavior: recommendations on optimal use","volume":"5","author":"Stirratt","year":"2015","journal-title":"Transl Behav Med"},{"issue":"Suppl. 4","key":"2026092511024236900_llag185-B31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2011.04060.x","article-title":"Maximizing patient adherence for optimal outcomes in psoriasis","volume":"25","author":"Bewley","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026092511024236900_llag185-B32","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s13555-022-00794-y","article-title":"Polyaphron dispersion technology, a novel topical formulation and delivery system combining drug penetration, local tolerability and convenience of application","volume":"12","author":"Praestegaard","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026092511024236900_llag185-B33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and Predictive Validity of a Self-Reported Measure of Medication Adherence and Long-Term Predictive Validity of Blood Pressure Control.","volume":"24","year":"1986","journal-title":"Med Care"},{"key":"2026092511024236900_llag185-B34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jclinepi.2010.09.010","article-title":"Improving the measurement of self-reported medication nonadherence: Final response.","volume":"64","author":"Morisky","year":"2011","journal-title":"J Clin Epidemiol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag185\/68184228\/llag185.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1855\/68184228\/llag185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1855\/68184228\/llag185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:03:08Z","timestamp":1790348588000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/10\/1855\/8664589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,4,29]]},"published-print":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag185","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,4,29]]}}}